CeleScreen

CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health. Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.